NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.06 +0.06 (+0.08%) GOLD FUTURES
2,313.40 +2.40 (+0.10%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,492.45 +1,439.09 (+3.12%)
Generation Bio Co. (GBIO)
After hours:
| Previous close | 2.9100 |
| Open | 2.9900 |
| Bid | 3.0900 x 200 |
| Ask | 3.1300 x 200 |
| Day's range | 2.9200 - 3.1300 |
| 52-week range | 0.8600 - 6.9800 |
| Volume | |
| Avg. volume | 247,650 |
| Market cap | 206.781M |
| Beta (5Y monthly) | 2.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.9600 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.50 |
GlobeNewswireGeneration Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that six abstracts highlighting preclinical data from its cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms have been accepted for presentation, including one oral presentation, at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking p
- GlobeNewswire
Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 12:45 p.m. ET. A live webcast of the presentation will be available on the investor section of the company’s w
- GuruFocus.com
Generation Bio Co Reports Full Year and Q4 2023 Financial Outcomes
Advancements in Genetic Medicine Platforms Highlighted Amid Financial Review
